Login to Your Account

Deals And M&A NEWS

Medivation Inc. will pay just $5 million up front, with the potential for another $85 million in development-based milestones and $245 million in sales milestones, for a stake in the PD-1 game through an exclusive global license to Curetech Ltd.'s late-stage molecule.

As its lead compound, telotristat etiprate (LX1032), marches toward the goal line, Lexicon Pharmaceuticals Inc. pocketed $23 million up front as part of a potential $145 million licensing deal with Paris-based Ipsen SA to commercialize the drug outside North America and Japan.

It's official. The board of directors at Dublin-based Shire plc agreed on Monday with Abbvie Inc. that its proposed $55 billion purchase of the Irish company is not going to happen.
More Deals And M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: